L3VLUP
ProSign in

NVST · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVSTVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVST
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterNVSTVRTX
Q3 20209 holders, $873m31 holders, $21.9bn
Q4 202011 holders, $1.4bn30 holders, $18.4bn
Q1 202113 holders, $2.4bn31 holders, $15.4bn
Q2 202116 holders, $2.1bn30 holders, $12.7bn
Q3 20219 holders, $1.4bn35 holders, $10.1bn
Q4 20217 holders, $1.6bn28 holders, $12.4bn
Q1 202210 holders, $2.3bn23 holders, $16.1bn
Q2 20229 holders, $1.8bn25 holders, $18.1bn
Q3 202211 holders, $1.4bn22 holders, $18.4bn
Q4 20229 holders, $812m28 holders, $18.4bn
Q1 202311 holders, $1.2bn26 holders, $21.4bn
Q2 202311 holders, $868m27 holders, $24.7bn
Q3 20239 holders, $694m33 holders, $24.3bn
Q4 202312 holders, $714m32 holders, $28.6bn
Q1 20249 holders, $393m31 holders, $29.8bn
Q2 20244 holders, $248m29 holders, $33.4bn
Q3 20244 holders, $312m27 holders, $33.5bn
Q4 20244 holders, $301m26 holders, $28.5bn
Q1 20254 holders, $263m21 holders, $35.4bn
Q2 20256 holders, $432m21 holders, $32.3bn
Q3 20255 holders, $359m22 holders, $25.9bn
Q4 20255 holders, $339m26 holders, $31.8bn
Q1 20268 holders, $392m25 holders, $31.8bn
Q2 20269 holders, $577m26 holders, $34.6bn
NVST

Envista Holdings Corporation

Holders
12
Reported value
$714m
Buyers
7
Sellers
6

Breadth +1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVST (3)

Balyasny Asset Management LLC, Harris Associates LP, Quantbot Technologies LP

Only VRTX (23)

Acadian Asset Management LLC, ARK Investment Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Maverick Capital Ltd, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →